Aether Bio develops machine learning algorithms and proprietary robotic hardware to engineer enzymes for the production of complex biochemical compounds. This technology enables manufacturers to create novel products at significantly reduced costs by efficiently indexing and searching trillions of enzyme sequences.
Funding
$101.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+2Founders
Product
Problem
Traditional enzyme engineering for complex biochemical compound production is slow and expensive, limiting the development of novel products and increasing manufacturing costs. Existing automation solutions lack the throughput necessary to efficiently explore the vast sequence space of potential enzymes.
Solution
Aether Bio has developed a platform that combines machine learning algorithms with proprietary robotic hardware to accelerate and reduce the cost of enzyme engineering. The company's technology indexes and searches trillions of enzyme sequences to identify novel biocatalysts for a wide range of chemistries. Aether's robotic factory runs millions of experiments in parallel, generating datasets orders of magnitude larger than those produced by conventional methods. This enables the design of enzymes for an expanding range of chemistries within practical timelines.
Target Audience
Aether Bio's primary customers are manufacturers in the chemical, pharmaceutical, and biotechnology industries seeking to produce complex and novel biochemical compounds at reduced costs.
Features
- Proprietary robotic hardware for massively parallelized experimentation and high-throughput enzyme screening
- Machine learning algorithms capable of searching trillions of enzyme sequences
- Technology to design enzymes for an ever increasing range of chemistries
- Ability to generate datasets orders of magnitude larger than the competition